Survival analysis and treatment effects in patients with endometrial cancer and POLE mutations
Cancer
.
2021 Nov 15;127(22):4306-4307.
doi: 10.1002/cncr.33806.
Epub 2021 Jul 27.
Authors
Simon Lamothe
1
,
Maximiliano Ramia de Cap
1
Affiliation
1
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
PMID:
34314028
DOI:
10.1002/cncr.33806
No abstract available
Publication types
Letter
Comment
MeSH terms
DNA Polymerase II / genetics
Endometrial Neoplasms* / genetics
Endometrial Neoplasms* / mortality
Endometrial Neoplasms* / therapy
Female
Humans
Mutation
Survival Analysis
Substances
DNA Polymerase II